【suing a church for negligence】Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
BERKELEY,suing a church for negligence CA
--(Marketwired - April 03, 2017) -
Dynavax Technologies Corporation
(
DVAX
)
announced today that the U.S. Food and Drug Administration (FDA) has informed the company that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] at its meeting scheduled for July 28, 2017. The scheduled VRBPAC meeting is close to the HEPLISAV-B Prescription Drug User Fee Act (PDUFA) date of August 10, 2017 solely as a function of meeting logistics. The PDUFA date remains unchanged. The FDA will communicate specific questions for the VRBPAC to address closer to the meeting date, and will post a draft agenda and draft questions on its website 48 hours prior to the meeting. HEPLISAV-B is the company's vaccine candidate for immunization against hepatitis B infection in adults ages 18 years of age and older.
"The notification of a VRBPAC meeting comes as no surprise and thus we are prepared for it," said Eddie Gray, chief executive officer of Dynavax. "The company looks forward to continuing to work with the FDA through the review process and discussing HEPLISAV-B with the advisory committee."
The VRBPAC reviews and evaluates data regarding the safety and efficacy of vaccines and related biological products that are intended for use in the prevention, treatment, or diagnosis of human diseases.
About Hepatitis B
Hepatitis B is a viral disease of the liver that can become chronic and can lead to cirrhosis of the liver, hepatocellular carcinoma and death. In the United States, the Centers for Disease Control and Prevention estimates that 19,000 hepatitis B infections continue to occur annually, with the vast majority occurring in adults. There is no cure for hepatitis B, and disease prevention through more effective vaccines is critical to reducing the spread of the disease.
About HEPLISAV-B
HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. In Phase 3 trials, HEPLISAV-B showed higher and earlier protection with fewer doses than a currently licensed hepatitis B vaccine. The most frequently reported local reaction was injection site pain. The most common systemic reactions were fatigue, headache and malaise, all of which were similar to an existing vaccine.
HEPLISAV-B is administered in two doses over one-month. Currently marketed hepatitis B vaccines are administered in three doses over a six-month schedule. Results of a published Vaccine Safety Datalink study showed that only 54 percent of adults completed the three-dose hepatitis B vaccine series in one year.
1
Those who do not complete the series may not be adequately protected against hepatitis B.
Dynavax has worldwide commercial rights to HEPLISAV-B.
About Dynavax
Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax's lead product candidates are SD-101, an investigational cancer immunotherapeutic currently in Phase 1/2 studies, and HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information, visit
www.dynavax.com
.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding HEPLISAV-B and FDA review. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the FDA will find the response to the CRL to be satisfactory to support approval; whether the FDA will require additional information or studies; whether the FDA will identify additional issues following review of Dynavax's response to the CRL; whether the VRBPAC meeting will be cancelled or postponed, will impact the timing of FDA review, negatively impact the review or whether the VRBPAC will recommend approval; whether additional manufacturing process enhancements will be required or other issues will arise that will negatively impact the review and approval by the FDA; if approvable, whether the issues will negatively impact the potential scope of the label for HEPLISAV-B; and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax's website at
www.dynavax.com
is not incorporated by reference in our current periodic reports with the SEC.
1
Nelson, J. et al. American Journal of Public Health, "Compliance with Multiple-Dose Vaccine Schedules Among Older Children, Adolescents and Adults: Results from a Vaccine Safety Datalink Study." 2009. Vol. 99 No. S2.
View comments
(责任编辑:Hotspot)
- Smithfield Foods Says That the Company and Its Team Members Want the Same Thing: To Protect Employee Health and Safety While Also Safeguarding America’s Food Supply
- Tesla's 'Full Self-Driving' feature is back on Autopilot
- Herman Cain for the Fed Board?
- With A 4.6% Return On Equity, Is Kilitch Drugs (India) Limited (NSE:KILITCH) A Quality Stock?
- How Does Duluth Holdings's (NASDAQ:DLTH) P/E Compare To Its Industry, After The Share Price Drop?
- SoftBank CEO Tells Wall Street He’s Eager to Keep Investing
- BRIEF-Hytera Communications' Consortium Wins Communication Equipment Contract In Philippines
- 4 Potential Drawbacks of 529 Plans and How to Minimize Them
- Nabors Industries Ltd (NBR) Files 10-K for the Fiscal Year Ended on December 31, 2018
- Storms that slammed Central America in 2020 just a preview, climate change experts say
- General Mills Stock Is Too Cheap to Ignore
- At €3.65, Is It Time To Put Derichebourg (EPA:DBG) On Your Watch List?
- Megyn Kelly Not Expected to Replace Matt Lauer on 'Today' -- Here's Who Might
-
240,000 U.S. Virus Deaths Don't Have to Happen
(Bloomberg Opinion) -- The Trump administration's Covid-19 task force prepared the country for the p ...[详细] -
Infighting Between Lanier and Objectors Over Fees Roils Hip Implant Litigation
Photo: ShutterstockA fight has erupted in thePinnacle hip implantlitigation over how much settlement ...[详细] -
Miley Cyrus performs as Black Mirror persona Ashley O at Glastonbury Festival
Oh honey,Miley Cyrus‘ll do anything for you… even transform into herBlack Mirroralter ego on stage.T ...[详细] -
Factbox: GM taps disaster fund expert for potential recall victims' fund
By Jessica Dye(Reuters) - General Motors Co said on Tuesday it has hired Kenneth Feinberg, a lawyer ...[详细] -
Gilead Sciences Could Be the First to Beat the Coronavirus
The coronavirus’ grip on the market continues. Since the beginning of February, the S&P 500 has shed ...[详细] -
Erik Prince had 'no knowledge' of training agreement in China's Xinjiang - spokesman
By Christian ShepherdBEIJING, Feb 1 (Reuters) - Former U.S. military contractor Erik Prince had "no ...[详细] -
Does Iron Road Limited (ASX:IRD) Have A Particularly Volatile Share Price?
If you’re interested in Iron Road Limited (ASX:IRD), then you might want to consider its beta (a mea ...[详细] -
Putin: Russia must improve port and airport infrastructure
MOSCOW, March 1 (Reuters) - Russia must improve its sea port infrastructure and expand its regional ...[详细] -
Great Ajax (AJX) Misses Q4 Earnings and Revenue Estimates
Great Ajax (AJX) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Es ...[详细] -
Should You Be Worried About Vista Group International Limited’s (NZSE:VGL) 8.0% Return On Equity?
While some investors are already well versed in financial metrics (hat tip), this article is for tho ...[详细]
3 Consumer Cyclical Mutual Funds to Grab in December
Brunswick (BC) Q4 2018 Earnings Conference Call Transcript
- Labrador Iron Ore Royalty Corporation Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
- 'No need to panic,' China official says of coronavirus variants
- Is B2Gold (TSE:BTO) A Risky Investment?
- Apple just confirmed the stock market's biggest fear
- A Trio of Strong Performers to Consider
- BRIEF-Shanghai Environment Plans Waste Disposal And Waste Incineration Power Projects
- FOREX-Dollar starts week on back foot, keeps above 4-mth lows